CVE:EPI - ESSA Pharma Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: C$0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
C$8.20
▲ +0.55 (7.19%)

This chart shows the closing price for EPI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ESSA Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EPI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EPI

Analyst Price Target is C$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for ESSA Pharma in the last 3 months. The average price target is C$0.00, with a high forecast of C$0.00 and a low forecast of C$10,000,000.00. The average price target represents a -100.00% upside from the last price of C$8.20.

This chart shows the closing price for EPI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in ESSA Pharma. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/31/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/26/2018HC WainwrightReiterated RatingBuy
1/18/2018Bloom BurtonUpgradeHold ➝ Buy
(Data available from 9/23/2016 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/25/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/25/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/24/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/23/2021

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.

ESSA Pharma

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.
Read More

Today's Range

Now: C$8.20
Low: C$7.33
High: C$8.20

50 Day Range

MA: C$8.20
Low: C$8.20
High: C$8.20

52 Week Range

Now: C$8.20
Low: C$4.00
High: C$11.34

Volume

1,430 shs

Average Volume

4,834 shs

Market Capitalization

C$237.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of ESSA Pharma?

The following Wall Street research analysts have issued research reports on ESSA Pharma in the last year:
View the latest analyst ratings for EPI.

What is the current price target for ESSA Pharma?

0 Wall Street analysts have set twelve-month price targets for ESSA Pharma in the last year. has the lowest price target set, forecasting a price of C$10,000,000.00 for ESSA Pharma in the next year.
View the latest price targets for EPI.

What is the current consensus analyst rating for ESSA Pharma?

ESSA Pharma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for EPI.

How do I contact ESSA Pharma's investor relations team?

ESSA Pharma's physical mailing address is 999 Broadway W Suite 720, VANCOUVER, BC V5Z 1K5, Canada. The company's listed phone number is +1-778-3310962. The official website for ESSA Pharma is essapharmaceuticals.com.